1. Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis. (February 2020) Authors: Nevens, F.; Shiffman, M.L.; Drenth, J.P.H.; Bowlus, C.L.; Vargas, V.; Andreone, P.; van Erpecum, K.; Floreani, A.; Liberman, A.; Pencek, R.; Malecha, E. Smoot; MacConell, L.; Trauner, M. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term efficacy and safety of obeticholic acid in patients with PBC from the POISE trial grouped biochemically by risk of disease progression. (March 2021) Authors: Bowlus, C.L.; Trauner, M.; Liberman, A.; Malecha, E.; MacConell, L.; Kremer, A.E.; Nevens, F.; Floreani, A. Journal: Digestive and liver disease Issue: Volume 53:(2021)Supplement 1 Page Start: S18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OC.01.4 THREE YEARS OF OBETICHOLIC ACID (OCA) THERAPY RESULTS IN HISTOLOGICAL IMPROVEMENTS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: FURTHER ANALYSIS OF THE POISE BIOPSY SUBSTUDY. (25th March 2019) Authors: Bowlus, C.L.; Pockros, P.; Kremer, A.; Pares, A.; Forman, L.M.; Drenth, J.P.; Ryder, S.; Floreani, A.; Terracciano, L.; Jin, Y.; Lieberman, A.; Pencheck, R.; Iloeje, U.; Macconell, L.; Bedossa, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 2 Page Start: e78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OC.04.7 LONG-TERM EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PBC FROM THE POISE TRIAL GROUPED BIOCHEMICALLY BY RISK OF DISEASE PROGRESSION. (September 2021) Authors: Floreani, A.; Bowlus, C.L.; Trauner, M.; Malecha, E.; Kremer, A.E.; Nevens, F. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. T06.01.3 DURABLE RESPONSE IN THE MARKERS OF CHOLESTASIS THROUGH 5 YEARS OF OPEN-LABEL EXTENSION STUDY OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS. (1st October 2020) Authors: Nevens, F.; Mitchell, S.; Drenth, J.P.; Bowlus, C.L.; Vargas, V.; Andreone, P.; Van Erpecum, K.; Floreani, A.; Lieberman, A.; Pencheck, R.; Smoot Malecha, E. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 2 Page Start: S158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy. (February 2019) Authors: Bowlus, C.L.; Pockros, P.J.; Kremer, A.E.; Parés, A.; Forman, L.M.; Drenth, J.P.H.; Ryder, S.; Terracciano, L.; Floreani, A.; Jin, Y.; Lieberman, A.; Pencek, R.; Iloeje, U.; MacConell, L.; Bedossa, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗